Keywords: Promethera Biosciences, Fund raising, HepaStem, Liver disease, Trial authorization, Shire, Boehringer Ingelheim
Promethera raises 23.6 million euros, with backers including Shire and Boehringer
Article | 28 March 2012
Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated 23.6 million euros ($31.3 million), including 17 million euros in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
